Two weeks until trial results, page-37

Let's just hope to have a serious share price increase based on the Phase II readout, and that any sort of agreement with a partner will be based on true market activities and not a pre-arranged crossover trade between the funds and the partner.

I do not understand yet if the catalyst in price will be the clinical trial readout or the partner agreement.

By absurd we could even get a readout with no major share price movements based on current performance.

We just have to wait and see what will happen. Up to now there is not too much to say. We all were expecting to be at a different price before the readout.
Currently., the SP is at a miserable 0.072.